BACKGROUND: CYP2B6 is the primary enzyme involved in bupropion (Zyban;
GlaxoSmithKline, Research Triangle Park, North Carolina) metabolism. Genetic
polymorphisms in CYP2B6, such as CYP2B6* 6, can alter bupropion metabolism and may
affect bupropion treatment outcome. METHODS: Subjects participated in a smoking
cessation clinical trial of bupropion versus placebo. The main outcome was a 7-day point
prevalence abstinence rate measured 10 weeks after the start of treatment (ie, end of …